If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, involved bone marrow, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides; decalcified sections will not be accepted; must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section). Pathology review by a Nationwide Children's Laboratory Services pathologist will be performed on all tumor samples to verify tumor percentage.

Fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, and unstained slides must contain minimum of ≥10% tumor content, while bone marrow requires ≥30% tumor content. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen. 

All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.

Send all samples via overnight courier service. Send snap-frozen or OCT-embedded tissue buried in dry ice. Send fresh tissue, paraffin-embedded tissue, or bone marrow at room temperature. Saturday deliveries are accepted; please check "Saturday Delivery" on shipment label for Saturday delivery. Please call (614) 722-5321 for any questions regarding this test. 

This test is a FISH analysis performed on tumor specimens and identifies amplification of the ALK oncogene locus. Presence or absence of ALK amplification may be used to help assign risk classification for the patient's neuroblastoma or other tumors.

Children with neuroblastoma (NBL) are assigned a specific risk group (low, intermediate, or high) based on a variety of clinical and biological factors. Nationwide Children's Laboratory Services offers targeted ALK sequencing and ALK amplification detection by FISH as orderable clinical testing. ALK amplification is present in approximately 2% of all NBL cases. ALK amplification is usually seen with MYCN (N-Myc) amplification. ALK amplification and ALK mutations are rarely found in the same tumor. Copy number gains involving ALK (not amplification) can occur in a subset of cases. These copy number gains typically involve the entire gain of chromosome 2 or 2p (rather than a focal gain of ALK). These copy number changes are also seen in conjunction with the presence of MYCN amplification.

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, involved bone marrow, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides; decalcified sections will not be accepted; must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section). Pathology review by a Nationwide Children's Laboratory Services pathologist will be performed on all tumor samples to verify tumor percentage.

Fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, and unstained slides must contain minimum of ≥10% tumor content, while bone marrow requires ≥30% tumor content. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen. 

All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.

Send all samples via overnight courier service. Send snap-frozen or OCT-embedded tissue buried in dry ice. Send fresh tissue, paraffin-embedded tissue, or bone marrow at room temperature. Saturday deliveries are accepted; please check "Saturday Delivery" on shipment label for Saturday delivery. Please call (614) 722-5321 for any questions regarding this test. 

This test is a FISH analysis performed on tumor specimens and identifies amplification of the ALK oncogene locus. Presence or absence of ALK amplification may be used to help assign risk classification for the patient's neuroblastoma or other tumors.

Children with neuroblastoma (NBL) are assigned a specific risk group (low, intermediate, or high) based on a variety of clinical and biological factors. Nationwide Children's Laboratory Services offers targeted ALK sequencing and ALK amplification detection by FISH as orderable clinical testing. ALK amplification is present in approximately 2% of all NBL cases. ALK amplification is usually seen with MYCN (N-Myc) amplification. ALK amplification and ALK mutations are rarely found in the same tumor. Copy number gains involving ALK (not amplification) can occur in a subset of cases. These copy number gains typically involve the entire gain of chromosome 2 or 2p (rather than a focal gain of ALK). These copy number changes are also seen in conjunction with the presence of MYCN amplification.

This test is a FISH analysis performed on tumor specimens and identifies amplification of the ALK oncogene locus. Presence or absence of ALK amplification may be used to help assign risk classification for the patient's neuroblastoma or other tumors.

Children with neuroblastoma (NBL) are assigned a specific risk group (low, intermediate, or high) based on a variety of clinical and biological factors. Nationwide Children's Laboratory Services offers targeted ALK sequencing and ALK amplification detection by FISH as orderable clinical testing. ALK amplification is present in approximately 2% of all NBL cases. ALK amplification is usually seen with MYCN (N-Myc) amplification. ALK amplification and ALK mutations are rarely found in the same tumor. Copy number gains involving ALK (not amplification) can occur in a subset of cases. These copy number gains typically involve the entire gain of chromosome 2 or 2p (rather than a focal gain of ALK). These copy number changes are also seen in conjunction with the presence of MYCN amplification.

If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, involved bone marrow, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides; decalcified sections will not be accepted; must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section). Pathology review by a Nationwide Children's Laboratory Services pathologist will be performed on all tumor samples to verify tumor percentage.

Fresh tissue, snap-frozen tissue, OCT-embedded tissue, paraffin-embedded tissue, and unstained slides must contain minimum of ≥10% tumor content, while bone marrow requires ≥30% tumor content. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen. 

All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.

Send all samples via overnight courier service. Send snap-frozen or OCT-embedded tissue buried in dry ice. Send fresh tissue, paraffin-embedded tissue, or bone marrow at room temperature. Saturday deliveries are accepted; please check "Saturday Delivery" on shipment label for Saturday delivery. Please call (614) 722-5321 for any questions regarding this test. 

This test is a FISH analysis performed on tumor specimens and identifies amplification of the ALK oncogene locus. Presence or absence of ALK amplification may be used to help assign risk classification for the patient's neuroblastoma or other tumors.

Children with neuroblastoma (NBL) are assigned a specific risk group (low, intermediate, or high) based on a variety of clinical and biological factors. Nationwide Children's Laboratory Services offers targeted ALK sequencing and ALK amplification detection by FISH as orderable clinical testing. ALK amplification is present in approximately 2% of all NBL cases. ALK amplification is usually seen with MYCN (N-Myc) amplification. ALK amplification and ALK mutations are rarely found in the same tumor. Copy number gains involving ALK (not amplification) can occur in a subset of cases. These copy number gains typically involve the entire gain of chromosome 2 or 2p (rather than a focal gain of ALK). These copy number changes are also seen in conjunction with the presence of MYCN amplification.